Millendo Therapeutics, Inc.
MLND · NASDAQ
12/31/2024 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $30 | $38 | $62 | $73 |
| Short-Term Investments | $0 | $0 | $0 | $4 |
| Receivables | $0 | $0 | $1 | $2 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $1 | $2 | $7 | $3 |
| Total Curr. Assets | $31 | $41 | $71 | $83 |
| Property Plant & Equip (Net) | $10 | $2 | $3 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $1 | $1 |
| Total NC Assets | $10 | $3 | $4 | $1 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $41 | $43 | $75 | $84 |
| Liabilities | – | – | – | – |
| Payables | $2 | $1 | $1 | $2 |
| Short-Term Debt | $7 | $1 | $2 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $5 | $6 | $9 | $8 |
| Total Curr. Liab. | $14 | $8 | $13 | $10 |
| LT Debt | $8 | $2 | $3 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $1 |
| Total NC Liab. | $8 | $2 | $3 | $1 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $22 | $10 | $15 | $11 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$207 | -$245 | -$209 | -$164 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $226 | $278 | $268 | $237 |
| Total Equity | $19 | $34 | $60 | $73 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $41 | $43 | $75 | $84 |
| Net Debt | -$15 | -$36 | -$58 | -$73 |